Pipeline

ViGeneron’s pipeline in gene therapy addresses ophthalmic diseases with high unmet medical need, including two lead programs in development for inherited retinal diseases where no approved treatment options are currently available.

For more information about the indications we are working on and the therapies our products offer, please click on the individual indication.

Program
Technology
platforms
Indication
Gene of interest
Partner
Discovery
In vitro
PoC
IND
enabling
Phase
I/II
Inherited Retinal Disease (IRD)
VG901
vgAAV
Retinitis Pigmentosa (RP)
>> more
Gene < 5kb
VG801
vgAAV + REVeRT
The most common IRD
>> more
Gene >5Kb
Undisclosed
vgAAV
IRD
Undisclosed
Undisclosed
vgAAV
IRD
Undisclosed
Prevalent Eye Diseases
Undisclosed
vgAAV
Age-related Macular Degeneration (AMD)
Novel non-VEGF
Undisclosed
vgAAV
Undisclosed
Undisclosed